Incyte Corporation (INCY) Receives Price Target

Incyte Corporation (INCY) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $135 and the lowest price target forecast is $90. The average forecast of all the analysts is $100.55 and the expected standard deviation is $12.47.

Incyte Corporation (INCY) has an average broker rating of 1.27, which is interpreted as a Strong Buy, as rated by 13 equity analysts. Nonetheless, 10 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.


Also, Equity Analysts at the Barclays maintains the rating on Incyte Corporation (NASDAQ:INCY). The brokerage firm has issued a Overweight rating on the shares. The Analysts at the ratings agency raises the price target from $85 per share to $100 per share. The rating by the firm was issued on August 10, 2016.

Incyte Corporation (NASDAQ:INCY): The stock opened at $81.61 on Thursday but the bulls could not build on the opening and the stock topped out at $81.73 for the day. The stock traded down to $79.89 during the day, due to lack of any buying support eventually closed down at $80.81 with a loss of -0.36% for the day. The stock had closed at $81.10 on the previous day. The total traded volume was 670,199 shares.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *